To use all functions of this page, please activate cookies in your browser.
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Vion Pharmaceuticals, Inc.
Vion Pharmaceuticals, Inc. (NASDAQ: VION) is a Connecticut based pharmaceutical company founded in March 1992 to commercialize several discoveries made in the biomedical laboratories at Yale University. Vion has been a publicly traded company on NASDAQ since 1995.
Additional recommended knowledge
Several anticancer programs are underway at Vion. Two small molecules, Cloretazine® (VNP40101M) and Triapine®, are in human clinical trials. Cloretazine® (VNP40101M), a novel alkylating agent, is in a Phase 3 trial in relapsed acute myelogenous leukemia (AML) and a Phase 2 trial in elderly de novo poor-risk AML. In addition, trials of Cloretazine® (VNP40101M) are underway in pediatric brain tumors, small cell lung cancer, and advanced hematologic malignancies. Triapine®, a ribonucleotide reductase inhibitor, is being evaluated in clinical trials sponsored by the National Cancer Institute.
|This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Vion_Pharmaceuticals,_Inc.". A list of authors is available in Wikipedia.|